TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26247661

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150 μg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (no iodine supplementation)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Maternal and cord blood thyroid tests
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: PCB 118 exposure
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TBG levels
Number of subjects: 86
Study: 24472478

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine (40 mg/m² as a 3-hour intravenous infusion every 3 weeks plus 1000 mg/m² oral capecitabine administered twice daily)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Capecitabine alone (1250 mg/m² administered twice daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 251

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 251
Study: 21110180

Group type: EXPERIMENTAL
Intervention: Aidi Injection (ADI) 100 mL added to 500 mL of 5% glucose injection, administered intravenously once daily for 14 days before each course of chemotherapy (total 28 days).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 60
Study: 18471329

Group type: EXPERIMENTAL
Intervention: Desflurane and fentanyl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane and fentanyl
Number of subjects: 20
Study: 16575715

Group type: EXPERIMENTAL
Intervention: Individual motivation programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 142
Study: 12921877

Group type: EXPERIMENTAL
Intervention: Diet 1 (higher carbohydrate, 72% energy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diet 2 (higher protein, 43% energy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Diet 3 (higher fat, 68% energy)
Number of subjects: 7
Study: 11001887

Group type: EXPERIMENTAL
Intervention: 5‐aza‐2'‐deoxycytidine (5‐aza‐CdR, decitabine) at doses ranging from 0.15 to 0.30 mg/kg given 5 days a week for 2 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 8
Study: 9085393

Group type: EXPERIMENTAL
Intervention: Experimental group (made 2,567 purchase attempts)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (made no purchase attempts)
Number of subjects: 48
Study: 8482458

Group type: EXPERIMENTAL
Intervention: Interferon alfa treatment
Number of subjects: 21
Study: 4036563

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study: 29080928

Group type: EXPERIMENTAL
Intervention: LED-Grandio®
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LED-Filtek™ Supremé
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halogen-Grandio®
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halogen-Filtek™ Supremé
Number of subjects: 100
Study: 27322379

Group type: EXPERIMENTAL
Intervention: Surgeons with high clinical experience (group C: >100 cases)
Number of subjects: 1406

Group type: COMPARATOR
Intervention: Surgeons with low clinical experience (group A: 50 cases)
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: High enrollment centers (group III: >75 patients)
Number of subjects: 1406

Group type: COMPARATOR
Intervention: Low enrollment centers (group I: <30 patients)
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: High annual volume centers (group 3: >75 cases)
Number of subjects: 1406

Group type: COMPARATOR
Intervention: Low annual volume centers (group 1: <40 carotid endarterectomies)
Number of subjects: 1406
Study: 24918560

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate (BT) 0.5% gel
Number of subjects: 553

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 553
Study: 22643538

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 180
Study: 20460620

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (500,000 IU)
Number of subjects: 2256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2256
Study: 18261195

Group type: EXPERIMENTAL
Intervention: Aripiprazole 2.5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 18
Study: 15721800

Group type: EXPERIMENTAL
Intervention: Cortisol administered before recall testing
Number of subjects: 16
Study: 12641876

Group type: EXPERIMENTAL
Intervention: Modifiable traditional risk factors (hypertension, dyslipidemia, diabetes mellitus, poor glycemic control, smoking, physical inactivity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment recommendations based on evidence from CKD populations or general population
Number of subjects: 0
Study: 11006055

Group type: EXPERIMENTAL
Intervention: Soymilk supplementation (400 mL daily for two menstrual cycles)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no soymilk supplementation)
Number of subjects: 60
Study: 8784280

Group type: EXPERIMENTAL
Intervention: Eutectic lidocaine/prilocaine 5% cream under occlusive dressing (Tegaderm)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Eutectic lidocaine/prilocaine 5% patch
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (lidocaine infiltration if analgesia was insufficient)
Number of subjects: 106
Study: 1732427

Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) 100 mg/m2 and Fluorouracil (5-FU) 1 g/m2 x 4
Number of subjects: 249

Group type: COMPARATOR
Intervention: Cisplatin (CP)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Fluorouracil (5-FU)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) and Fluorouracil (5-FU) combination
Number of subjects: 249
Study: 6365809

Group type: EXPERIMENTAL
Intervention: sfericase (6 tablets/day)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: sfericase (2 tablets, 3X/day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: inactive placebo
Number of subjects: 109
Study: 30293937

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug treatment (LLT)
Number of subjects: 4257

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug treatment (LLT) in highest risk tertile
Number of subjects: 4257

Group type: COMPARATOR
Intervention: No LLT
Number of subjects: 4257
Study: 27553762

Group type: EXPERIMENTAL
Intervention: Intraoperative instructional videos
Number of subjects: 21

Group type: COMPARATOR
Intervention: Preoperative instructional videos
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 28031038

Group type: EXPERIMENTAL
Intervention: Smartphone app intervention for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control (access to the app after 4 weeks)
Number of subjects: 100
Study: 24438039

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 23099111

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral Weight-Loss-Treatment (BWLT)
Number of subjects: 0
Study: 19958982

Group type: EXPERIMENTAL
Intervention: TEVAR using GORE TAG device
Number of subjects: 59
Study: 17563981

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus basic therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 65
Study: 15119705

Group type: EXPERIMENTAL
Intervention: Condensable material Admira (group 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Flowable material Admira Flow (group 2)
Number of subjects: 25
Study: 11549652

Group type: EXPERIMENTAL
Intervention: 0.625 mg oral conjugated E
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 60 mg droloxifene
Number of subjects: 35
Study: 9625092

Group type: EXPERIMENTAL
Intervention: High-sucrose diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-starch diet
Number of subjects: 8
Study: 7932018

Group type: EXPERIMENTAL
Intervention: Transplanted teeth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teeth
Number of subjects: 0
Study: 3065099

Group type: EXPERIMENTAL
Intervention: Cerulein at 100 ng/kg/h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cerulein at 50 ng/kg/h
Number of subjects: 6
Study: 29794305

Group type: EXPERIMENTAL
Intervention: Neck stabilisation exercise group (NSEG; n=30)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Neck dynamic exercise group (NDEG; n=28)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Neck stabilisation and dynamic exercise group (NSDEG; n=31)
Number of subjects: 89
Study: 28224367

Group type: EXPERIMENTAL
Intervention: MOC31PE immunotoxin administered intraperitoneally as a single dose after CRS-HIPEC with Mitomycin C
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MOC31PE immunotoxin
Number of subjects: 15
Study: 25319807

Group type: EXPERIMENTAL
Intervention: Adjuvant interferon alfa-2b (IFN-α) therapy for 12 or 24 months
Number of subjects: 460

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 460
Study: 25128049

Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy with Low Glucose Suspend (LGS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pump therapy with self-monitoring of blood glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump therapy with LGS
Number of subjects: 0
Study: 22935853

Group type: EXPERIMENTAL
Intervention: Routine exercise plus stabilization training for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine exercise only
Number of subjects: 30
Study: 19239946

Group type: EXPERIMENTAL
Intervention: Incision drainage with buttoning
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Surgical deroofing with buttoning
Number of subjects: 29

Group type: COMPARATOR
Intervention: Aspiration with contour dressing
Number of subjects: 29

Group type: COMPARATOR
Intervention: Incision drainage
Number of subjects: 29
Study: 17560730

Group type: COMPARATOR
Intervention: Mirtazapine monotherapy (n=13)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination therapy with mirtazapine and lithium (n=13)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mirtazapine monotherapy (n=10)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination treatment with mirtazapine and carbamazepine (n=10)
Number of subjects: 46
Study: 15219296

Group type: COMPARATOR
Intervention: Benzocaine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Viscous Lidocaine
Number of subjects: 82
Study: 11570432

Group type: EXPERIMENTAL
Intervention: DASH diet with sodium restriction
Number of subjects: 0

Group type: COMPARATOR
Intervention: DASH diet without sodium restriction
Number of subjects: 0
Study: 10036794

Group type: EXPERIMENTAL
Intervention: 6% medium molecular weight hydroxyethylstarch solution made of potato (K)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6% medium molecular weight hydroxyethylstarch solution made of corn (M)
Number of subjects: 20
Study: 8817803

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2161308

Group type: EXPERIMENTAL
Intervention: OVT-n (nonoxynol-9)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OVT-m (menfegol)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both OVT-n and OVT-m
Number of subjects: 102
Study: 7285485

Group type: EXPERIMENTAL
Intervention: Cimetidine (1000 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31739276

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (iCBT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Active control group (psychoeducation, monitoring and clinical support)
Number of subjects: 82
Study: 31638341

Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-617 (8.5 GBq decreasing by 0.5 GBq per cycle) i.v. every 6 weeks, for up to a maximum of six cycles
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cabazitaxel (20 mg/m2) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles
Number of subjects: 200
Study: 26646596

Group type: EXPERIMENTAL
Intervention: Chinese hand massage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (conventional therapies and care)
Number of subjects: 100
Study: 25637811

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24834493

Group type: EXPERIMENTAL
Intervention: Yogic practice (yogasana, pranayama, and meditation) for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Physical training (control group) for 3 months
Number of subjects: 64
Study: 22945541

Group type: EXPERIMENTAL
Intervention: Stage-matched care (SMC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 110
Study: 21195962

Group type: EXPERIMENTAL
Intervention: Intravenous conscious sedation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral analgesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18707659

Group type: EXPERIMENTAL
Intervention: Real-time feedback on forces applied during surgical tasks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Blind group (no feedback)
Number of subjects: 12
Study: 17156179

Group type: EXPERIMENTAL
Intervention: Vouchers for 6 months of methadone treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: Case management without vouchers
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of both interventions
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Vouchers alone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 12838103

Group type: EXPERIMENTAL
Intervention: sEMG and ROM measurements before rehabilitation (n=54)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: sEMG and ROM measurements after rehabilitation (n=34)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: sEMG and ROM measurements (Part 1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Flexion-relaxation measures
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: sEMG for identifying abnormal motion
Number of subjects: 66
Study: 10700368

Group type: EXPERIMENTAL
Intervention: Brief family intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 9849834

Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD) with triple therapy of colimycin, tobramycin, and nystatin administered orally or via nasogastric tube every 6 hours, plus oropharyngeal decontamination with hexitidine for patients with mechanical ventilation or immune-depression.
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (no SDD treatment)
Number of subjects: 244
Study: 8044943

Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rTPA) therapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 310
Study: 2566536

Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 41

Group type: COMPARATOR
Intervention: 120 mg terfenadine
Number of subjects: 41
Study: 4586043

Group type: EXPERIMENTAL
Intervention: Millipore filter unit
Number of subjects: 0
Study: 30571923

Group type: EXPERIMENTAL
Intervention: Standardized rehabilitation therapy
Number of subjects: 260
Study: 28867601

Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 60
Study: 25811889

Group type: COMPARATOR
Intervention: Watchful waiting (control arm)
Number of subjects: 194
Study: 23443650

Group type: EXPERIMENTAL
Intervention: Size selected by matching O-C with SLIPA™ chamber length (Group A, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Size selected by matching the width of the thyroid cartilage with the widest dimension of the SLIPA™ (Group B, n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study: 21477197

Group type: EXPERIMENTAL
Intervention: Non-verbal reasoning training (15 min/day for 25 days)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination training (non-verbal reasoning + working memory)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo version of the combined training
Number of subjects: 101
Study: 18959646

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 58

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 58
Study: 17065896

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 46
Study: 12581938

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management (CBSM) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11938856

Group type: EXPERIMENTAL
Intervention: DMPS plus Gandou tablet
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: DMPS
Number of subjects: 146

Group type: COMPARATOR
Intervention: EDTA
Number of subjects: 146
Study: 9171689

Group type: EXPERIMENTAL
Intervention: Partners in Patient Care delivery model (PIPC)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 2
Study: 8137583

Group type: EXPERIMENTAL
Intervention: Intraperitoneal distribution imaging (IDI) using 1000 ml of normal saline and 1 mCi of Tc‐99m SC
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low volumes of saline for IDI
Number of subjects: 8
Study: 2461401

Group type: EXPERIMENTAL
Intervention: Skin test reagents from two companies
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Skin test reagents from all companies
Number of subjects: 87
Study: 31985725

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30829771

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 64 U (FHL 20 U, GL 20 U, CFL 24 U)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 40 U (FHL 20 U, GL 20 U, CFL placebo)
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (both dosages)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Repeated onabotulinumtoxinA 64 U treatment in Period 2
Number of subjects: 787
Study: 30643391

Group type: EXPERIMENTAL
Intervention: Quesero XR 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Seroquel XR 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 20
Study: 28366518

Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with corifollitropin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional daily gonadotropins (recombinant FSH and highly purified human menopausal gonadotrophin)
Number of subjects: 0
Study: 24243931

Group type: COMPARATOR
Intervention: Room temperature tumescence anesthesia (+24℃)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cold tumescence anesthesia (+4℃)
Number of subjects: 101
Study: 24042190

Group type: EXPERIMENTAL
Intervention: Covered self-expandable metal stents (SEMSs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Uncovered self-expandable metal stents (SEMSs)
Number of subjects: 120
Study: 21585690

Group type: EXPERIMENTAL
Intervention: Decision aids for mastectomy versus breast-conserving therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision aids for axillary dissection versus sentinel node biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 0
Study: 19450071

Group type: EXPERIMENTAL
Intervention: Radiation treatment schedules
Number of subjects: 187

Group type: COMPARATOR
Intervention: Medicare patients
Number of subjects: 187

Group type: COMPARATOR
Intervention: Non-Medicare patients
Number of subjects: 187
Study: 17008803

Group type: EXPERIMENTAL
Intervention: Induction therapy with twice-daily IFN-beta (3X2=6 million units/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Consensus interferon monotherapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Induction therapy with twice-daily IFN-beta
Number of subjects: 28
Study: 12933575

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 3 mg/m2 with induction chemotherapy (DAT, DA, or FLAG-Ida)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DA or FLAG-Ida with GO in induction
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GO 3 mg/m2 with consolidation (MACE or HidAC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Thioguanine-containing schedules
Number of subjects: 72
Study: 10833803

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9120460

Group type: EXPERIMENTAL
Intervention: Chronic inflammatory demyelinating polyneuropathy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hereditary motor sensory neuropathy type I
Number of subjects: 32

Group type: COMPARATOR
Intervention: Guillain‐Barre syndrome
Number of subjects: 32
Study: 1551155

Group type: EXPERIMENTAL
Intervention: Halothane 3.5% in humidified oxygen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane 5% in humidified oxygen
Number of subjects: 40
Study: 3901465

Group type: EXPERIMENTAL
Intervention: Examinations by different technologists
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Obtaining the velocity waveforms
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Classifying the extent of carotid disease
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intraobserver variability in rereading spectral waveforms
Number of subjects: 48
Study: 31628791

Group type: EXPERIMENTAL
Intervention: eMBCT
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: MBCT
Number of subjects: 245
Study: 30167646

Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device (IASD; Corvia Medical)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 43
Study: 26975225

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Standard strategy
Number of subjects: 1059
Study: 23830769

Group type: EXPERIMENTAL
Intervention: Kinesiologic tape (KT) applied postoperatively for at least 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kinesiologic tape (KT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No kinesiologic tape (control)
Number of subjects: 30